P. Leber

发表

Sudden death as a risk of neuroleptic treatment: (a continuing controversy).

P. Leber, 1981, Psychopharmacology bulletin.

If Placebo Works, Could, Should or Would it be Approved for Marketing?

E. Laska, P. Leber, 2002 .

Is there an alternative to the randomized controlled trial?

P. Leber, 1991, Psychopharmacology bulletin.

Micropuncture study of concentration and fate of albumin in rat nephron.

D. Marsh, P. Leber, 1970, The American journal of physiology.

A REGULATORY PERSPECTIVE

P. Leber, 1986 .

Experimental cell-mediated interstitial nephritis induced with exogenous antigens.

M. V. van Zwieten, A. Bhan, P. Leber, 1977, Journal of immunology.

ALTERED FUNCTIONAL PROPERTIES OF THE RENAL GLOMERULUS IN AUTOLOGOUS IMMUNE COMPLEX NEPHRITIS

M. Karnovsky, E. Schneeberger, P. Leber, 1974, The Journal of experimental medicine.

ALTERED FUNCTIONAL PROPERTIES OF THE RENAL GLOMERULUS IN AUTOLOGOUS IMMUNE COMPLEX NEPHRITIS

M. Karnovsky, E. Schneeberger, P. Leber, 1974, The Journal of experimental medicine.

ALTERED F UNCTIONAL P ROPERTIES OF THE R ENAL GLOMERULUS I N AUTOLOGOUS IMMUNE COMPLEX N EPHRITIS AN ULTRASTRUCTURAL TRACER STUDY

M. Karnovsky, E. Schneeberger, P. Leber, 1974 .

Adverse drug reactions. Safe passage (how good a guarantee?).

P. Leber, 1982, Psychopharmacology bulletin.

Not in our methods, but in our ignorance.

P. Leber, 2002, Archives of general psychiatry.

Complement and the immunohistology of renal disease.

P. Leber, R. McCluskey, 1974, Transplantation proceedings.

"Time-less" risks (a hazard of risk assessment: the example of seizure and antidepressants).

P. Leber, 1985, Psychopharmacology bulletin.

Eosinophils in delayed hypersensitivity skin reaction sites.

P. Leber, M. Milgrom, S. Cohen, 1973, Immunological communications.

Hazards of Inference: The Active Control Investigation

P. Leber, 1989, Epilepsia.

Placebo controls: no news is good news.

P. Leber, 2000, Archives of general psychiatry.

The use of placebo control groups in the assessment of psychiatric drugs: an historical context

Paul Leber, P. Leber, 2000, Biological Psychiatry.

Threats to the validity of clinical trials employing enrichment strategies for sample selection.

C. S. Davis, C. S. Davis, P D Leber, 1998, Controlled clinical trials.

Treatment of Alzheimer's disease -- searching for a breakthrough, settling for less.

D. Drachman, P. Leber, 1997, The New England journal of medicine.

Observations and Suggestions on Antidementia Drug Development

P Leber, P. Leber, 1996, Alzheimer disease and associated disorders.

Slowing the progression of Alzheimer disease: methodologic issues.

P Leber, P. Leber, P. Leber, 1997, Alzheimer disease and associated disorders.

Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

S Shimohama, L. Thal, R. Mohs, 1997, Alzheimer disease and associated disorders.

Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group.

M N Rossor, R J Harvey, S Shimohama, 1997, Alzheimer disease and associated disorders.